Using Machine learning to predict medication therapy problems among patients with chronic kidney disease.

IF 4.3 3区 医学 Q1 UROLOGY & NEPHROLOGY
Alaa A Alghwiri, Melanie R Weltman, Linda-Marie U Lavenburg, Zhuoheng Han, Thomas D Nolin, Yi-Fan Chen, Jonathan G Yabes, Manisha Jhamb
{"title":"Using Machine learning to predict medication therapy problems among patients with chronic kidney disease.","authors":"Alaa A Alghwiri, Melanie R Weltman, Linda-Marie U Lavenburg, Zhuoheng Han, Thomas D Nolin, Yi-Fan Chen, Jonathan G Yabes, Manisha Jhamb","doi":"10.1159/000546540","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Patients with chronic kidney disease (CKD) are at risk of medication therapy problems (MTP) due to high comorbidity and medication burden. Using data from the Kidney Coordinated HeAlth Management Partnership (Kidney CHAMP) trial, we used machine learning to build a predictive model to identify MTP high-risk patients with CKD in the primary care setting.</p><p><strong>Methods: </strong>We used baseline data from patients enrolled in the intervention arm of the Kidney CHAMP trial, completed May 2019 to July 2022, which tested a population health management strategy, including medication management, for improving CKD care. The dataset was divided into 80% training and 20% testing subsets. The area under the ROC curve (AUROC) was used to assess classification accuracy in distinguishing between patients with and without MTP. Eight candidate models were considered, and the top three performing models (Random Forest, Support Vector Machines, and Gradient Boosting), based on cross-validated AUROC on training data, underwent further refinement. The model with the highest AUROC in the testing set, while considering the bias/variance trade-off, was selected as the best-performing model. SHapley Additive exPlanations (SHAP) was then leveraged using the best-performing model to evaluate the impact of each predictor to the final risk score.</p><p><strong>Results: </strong>Among 730 patients who received medication review at baseline, 566 (77.5%) had at least 1 MTP. Key demographics were mean age 74 years, 55% females, 92% White, 64% with diabetes, and the mean number of medications was 5.8 at baseline. The Random Forest model had the best performance on the testing set with AUROC 0.72, sensitivity 0.80, and specificity 0.64. The five most influential variables, ranked in descending order of importance for predicting individuals with MTP, were diabetes status (yes/no), hemoglobin A1C (HbA1C), urine albumin-to-creatinine ratio (UACR), systolic blood pressure, and age.</p><p><strong>Conclusion: </strong>In outpatient primary care, a machine learning-based MTP risk calculator that use routinely available clinical data can identify patients with moderate-high risk CKD who are at high risk for developing MTPs.</p>","PeriodicalId":7570,"journal":{"name":"American Journal of Nephrology","volume":" ","pages":"1-16"},"PeriodicalIF":4.3000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546540","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Patients with chronic kidney disease (CKD) are at risk of medication therapy problems (MTP) due to high comorbidity and medication burden. Using data from the Kidney Coordinated HeAlth Management Partnership (Kidney CHAMP) trial, we used machine learning to build a predictive model to identify MTP high-risk patients with CKD in the primary care setting.

Methods: We used baseline data from patients enrolled in the intervention arm of the Kidney CHAMP trial, completed May 2019 to July 2022, which tested a population health management strategy, including medication management, for improving CKD care. The dataset was divided into 80% training and 20% testing subsets. The area under the ROC curve (AUROC) was used to assess classification accuracy in distinguishing between patients with and without MTP. Eight candidate models were considered, and the top three performing models (Random Forest, Support Vector Machines, and Gradient Boosting), based on cross-validated AUROC on training data, underwent further refinement. The model with the highest AUROC in the testing set, while considering the bias/variance trade-off, was selected as the best-performing model. SHapley Additive exPlanations (SHAP) was then leveraged using the best-performing model to evaluate the impact of each predictor to the final risk score.

Results: Among 730 patients who received medication review at baseline, 566 (77.5%) had at least 1 MTP. Key demographics were mean age 74 years, 55% females, 92% White, 64% with diabetes, and the mean number of medications was 5.8 at baseline. The Random Forest model had the best performance on the testing set with AUROC 0.72, sensitivity 0.80, and specificity 0.64. The five most influential variables, ranked in descending order of importance for predicting individuals with MTP, were diabetes status (yes/no), hemoglobin A1C (HbA1C), urine albumin-to-creatinine ratio (UACR), systolic blood pressure, and age.

Conclusion: In outpatient primary care, a machine learning-based MTP risk calculator that use routinely available clinical data can identify patients with moderate-high risk CKD who are at high risk for developing MTPs.

使用机器学习预测慢性肾脏疾病患者的药物治疗问题。
慢性肾脏疾病(CKD)患者由于高合并症和药物负担,存在药物治疗问题(MTP)的风险。使用肾脏协调健康管理伙伴关系(Kidney CHAMP)试验的数据,我们使用机器学习建立预测模型,以识别初级保健机构中MTP高危CKD患者。方法:我们使用了肾CHAMP试验干预组患者的基线数据,该试验于2019年5月至2022年7月完成,该试验测试了包括药物管理在内的人群健康管理策略,以改善CKD护理。数据集被分为80%的训练子集和20%的测试子集。ROC曲线下面积(AUROC)用于评估区分MTP患者和非MTP患者的分类准确性。我们考虑了8个候选模型,并基于训练数据的交叉验证AUROC对表现最好的3个模型(Random Forest、Support Vector Machines和Gradient Boosting)进行了进一步的细化。在考虑偏差/方差权衡的情况下,选择AUROC最高的模型作为表现最好的模型。沙普利加性解释(SHapley Additive explanation, SHAP)然后利用表现最好的模型来评估每个预测因子对最终风险评分的影响。结果:在基线接受药物回顾的730例患者中,566例(77.5%)至少有1次MTP。主要人口统计数据为平均年龄74岁,55%为女性,92%为白人,64%为糖尿病患者,基线时平均用药次数为5.8次。随机森林模型在测试集上表现最佳,AUROC为0.72,灵敏度为0.80,特异性为0.64。预测MTP个体的五个最具影响力的变量(按重要性降序排列)是糖尿病状态(是否)、血红蛋白A1C (HbA1C)、尿白蛋白与肌酐比(UACR)、收缩压和年龄。结论:在门诊初级保健中,使用常规临床数据的基于机器学习的MTP风险计算器可以识别中高风险CKD患者,这些患者发展为MTP的风险很高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American Journal of Nephrology
American Journal of Nephrology 医学-泌尿学与肾脏学
CiteScore
7.50
自引率
2.40%
发文量
74
审稿时长
4-8 weeks
期刊介绍: The ''American Journal of Nephrology'' is a peer-reviewed journal that focuses on timely topics in both basic science and clinical research. Papers are divided into several sections, including:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信